273 related articles for article (PubMed ID: 25101080)
1. The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantation.
Heidegger S; van den Brink MR; Haas T; Poeck H
Front Immunol; 2014; 5():337. PubMed ID: 25101080
[TBL] [Abstract][Full Text] [Related]
2. Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases.
Tu S; Zhong D; Xie W; Huang W; Jiang Y; Li Y
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27529218
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation.
Toubai T; Guoqing H; Rossi C; Mathewson N; Oravecz-Wilson K; Cummings E; Wu J; Sun Y; Choi S; Reddy P
Oncoimmunology; 2015 Jul; 4(7):e1016699. PubMed ID: 26140241
[TBL] [Abstract][Full Text] [Related]
5. IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity.
Lu Y; Giver CR; Sharma A; Li JM; Darlak KA; Owens LM; Roback JD; Galipeau J; Waller EK
Blood; 2012 Jan; 119(4):1075-85. PubMed ID: 22130799
[TBL] [Abstract][Full Text] [Related]
6. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
7. Metabolic Targets for Improvement of Allogeneic Hematopoietic Stem Cell Transplantation and Graft-vs.-Host Disease.
Tijaro-Ovalle NM; Karantanos T; Wang HT; Boussiotis VA
Front Immunol; 2019; 10():295. PubMed ID: 30891031
[TBL] [Abstract][Full Text] [Related]
8. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
9. New developments in allotransplant immunology.
Barrett AJ; Rezvani K; Solomon S; Dickinson AM; Wang XN; Stark G; Cullup H; Jarvis M; Middleton PG; Chao N
Hematology Am Soc Hematol Educ Program; 2003; ():350-71. PubMed ID: 14633790
[TBL] [Abstract][Full Text] [Related]
10. Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.
Mammadli M; Huang W; Harris R; Xiong H; Weeks S; May A; Gentile T; Henty-Ridilla J; Waickman AT; August A; Bah A; Karimi M
iScience; 2021 Apr; 24(4):102286. PubMed ID: 33851101
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
12. The Role of Co-stimulatory/Co-inhibitory Signals in Graft-vs.-Host Disease.
Kumar S; Leigh ND; Cao X
Front Immunol; 2018; 9():3003. PubMed ID: 30627129
[TBL] [Abstract][Full Text] [Related]
13. [Immune tolerance induced by cytokines in allogeneic hematopoietic stem cell transplantation].
Chang YJ; Huang XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Apr; 41(2):208-11. PubMed ID: 19377632
[TBL] [Abstract][Full Text] [Related]
14. The Ex Vivo Treatment of Donor T Cells with Cosalane, an HIV Therapeutic and Small-Molecule Antagonist of CC-Chemokine Receptor 7, Separates Acute Graft-versus-Host Disease from Graft-versus-Leukemia Responses in Murine Hematopoietic Stem Cell Transplantation Models.
Fowler KA; Li K; Whitehurst CB; Bruce DW; Moorman NJ; Aubé J; Coghill JM
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1062-1074. PubMed ID: 30668984
[TBL] [Abstract][Full Text] [Related]
15. Danger Signals and Graft-versus-host Disease: Current Understanding and Future Perspectives.
Toubai T; Mathewson ND; Magenau J; Reddy P
Front Immunol; 2016; 7():539. PubMed ID: 27965667
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-22 in Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation.
Lamarthée B; Malard F; Saas P; Mohty M; Gaugler B
Front Immunol; 2016; 7():148. PubMed ID: 27148267
[TBL] [Abstract][Full Text] [Related]
17. Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation.
Song Y; Zhu Y; Hu B; Liu Y; Lin D; Jin Z; Yin Z; Dong C; Wu D; Liu H
Front Immunol; 2020; 11():558143. PubMed ID: 33178187
[TBL] [Abstract][Full Text] [Related]
18. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
19. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice.
Shimoni A; Nagler A
Cancer Treat Res; 2002; 110():113-36. PubMed ID: 11908195
[TBL] [Abstract][Full Text] [Related]
20. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
